Rain has built a pipeline of targeted oncology therapies. For more information on each of our programs, please visit our Science page.
Program Overview

Program | Indication / Strategy | Phase |
---|---|---|
RAIN-32 (DS-3032) MDM2 |
WD / DD Liposarcoma | Phase 2 |
MDM2 Basket Study | Phase 1a | |
AML: FLT3-ITD / Quizartinib | Phase 1a | |
Tarloxotinib Pan-HER |
NSCLC: HER2 Ex20 | Phase 2 |
Basket: NRG1 / HER Fusions1 | Phase 2 | |
RAD52 Research Program | PARP-relapsed. HRD+Tumors | Preclinical |
BRCA-deficient tumors | Preclinical |
1. Includes EGFR kinase domain duplications (KDD), EGFR fusions, ERBB2, and ERBB4 fusions